Mark A. Socinski, MD, AdventHealth Cancer Institute

Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.

The potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.

Mark Socinski, MD, Gilberto Lopes, MD, and Jack West, MD, provide an overview of the role of EGFR-targeted TKIs in NSCLC and the costs.

Recommendations for EGFR testing in patients with non–small cell lung cancer based on the wide heterogeneity of these mutations.

Mark A. Socinski, MD, highlights the targeted agents available to treat non–small cell lung cancer with EGFR mutations.

Recommendations for mitigating and managing common treatment-related adverse events associated with mobocertinib and other tyrosine kinase inhibitors.

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on the impact of payers when dealing with the cost of treatments.

Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, discuss personalized treatment plans based on innovative therapies and affordability.

Commentary on the use of EGFR tyrosine kinase inhibitors and their efficacy on non–small cell lung cancer brain metastases.

Potential implications for treating patients with metastatic non–small cell lung cancers with EGFR exon 20 insertion mutations with mobocertinib, based on the EXCLAIM cohort.

Rare drivers such as EGFR exon 20 insertions and what they mean for treatment of patients with metastatic non–small cell lung cancer.

Mark A. Socinski, MD shares a brief overview of the biomarkers and FDA-approved targeted therapies for non–small cell lung cancers.

The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

Experts in various specialties of oncology management share their insights on the role of financial toxicity on making treatment decisions for patients.

Jack West, MD, Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, provide a definition for financial toxicity.

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

Variables that influence patient selection for durvalumab consolidation after CRT as part of treatment for unresectable stage III non–small cell lung cancer.

How to differentiate whether a patient with unresectable stage III non–small cell lung cancer develops pneumonitis from chemoradiation or durvalumab, and insight regarding techniques to help manage treatment toxicities.

Chaitali Nangia, MD, of the Patty and George Hoag Cancer Center, reacts to the significance of the 5-year overall survival data for the PACIFIC trial evaluating the use of durvalumab after chemoradiation as treatment for inoperable stage III non–small cell lung cancer.

Second-line treatment recommendations for patients with stage IV non–small cell lung cancer who experience disease progression after immunotherapy.

Future projections regarding the role of novel I-O therapies as frontline treatment for patients with metastatic non–small cell lung cancer.

Recommendations for managing immune-related adverse events associated with checkpoint inhibitors used to treat stage IV non–small cell lung cancer.

Martin Dietrich, MD, PhD, shares his thoughts on PD-L1 status, tumor mutational burden, and other predictive and prognostic biomarkers when making treatment decisions for patients with stage IV non–small cell lung cancer.

Considerations for selecting frontline therapy for metastatic non–small cell lung cancer based on various new data and treatment approvals in the field of immunotherapy.

Neal Edward Ready, MD, PhD, describes which patients with stage IV non–small cell lung cancer may benefit from the combination of ipilimumab and nivolumab in the frontline treatment setting.